BioCentury
ARTICLE | Clinical News

Plecanatide: Phase III started

May 5, 2014 7:00 AM UTC

Synergy began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 3 and 6 mg oral plecanatide once daily for 12 weeks in 1,350 patients with CIC. Synergy said this is the second Phase...